Pavmed (PAVM) Stock News

PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for August 13, 2024, at 8:30 AM ET. During the call, Chairman and CEO Lishan Aklog, M.D., will provide an overview of the company's operations and growth strategy, while President and CFO Dennis McGrath will discuss second quarter 2024 financial results.

Investors can access the webcast through PAVmed's website or join the conference call by dialing 1-800-836-8184 (U.S.) or 1-646-357-8785 (international). The call name is "PAVmed Business Update". A 30-day replay will be available on the company's website following the call.

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company, has announced a business update conference call and webcast scheduled for August 12, 2024, at 8:30 AM ET. The event will feature:

• A business update and overview of operations by CEO Lishan Aklog, M.D.
• Discussion of the company's growth strategy
• Presentation of Q2 2024 financial results by CFO Dennis McGrath

Interested parties can access the webcast via the investor relations section of luciddx.com. For telephone access, U.S. callers should dial 1-800-836-8184, while international listeners should use 1-646-357-8785. The conference call name is "Lucid Diagnostics Business Update". A 30-day replay will be available on the company's website after the call.

Lucid Diagnostics Inc. (Nasdaq: LUCD) reported a record-breaking quarter for its EsoGuard® Esophageal DNA test volume. In Q2 2024, the company performed 3,174 tests, marking a 31% increase from Q1. This growth is attributed to expanded awareness and demand for EsoGuard esophageal precancer testing across various healthcare settings.

CEO Lishan Aklog emphasized the company's focus on increasing access to EsoGuard testing. Lucid expects to release full Q2 2024 results in mid-August. Additionally, the company held a productive meeting with CMS Medicare Administrative Contractor Palmetto GBA's Molecular Diagnostics Program (MolDX), which included key executives and medical experts in gastroenterology.

Lucid Diagnostics (Nasdaq: LUCD), a company focused on cancer prevention medical diagnostics, has launched a newly redesigned corporate website (www.luciddx.com) as announced on July 11, 2024. This improved platform aims to provide an enhanced user experience for patients, healthcare professionals, investors, and other stakeholders. According to Jenna Mowatt, Vice President of Marketing and Communications, the website is designed to reflect the company's mission to prevent esophageal cancer and showcase its innovative technologies through a modern design and comprehensive content. Lucid Diagnostics encourages visitors to explore the new website for more information.

Lucid Diagnostics announced positive results from its ESOGUARD BE-1 clinical validation study for EsoGuard, a test for detecting esophageal precancer. The study showed an 87.5% sensitivity and a 98.6% negative predictive value (NPV). The study was conducted across multiple international centers, including major U.S. and European institutions. The results support the upcoming Medicare LCD pre-submission and ongoing commercial payor engagements. The study involving 93 subjects confirmed the test's efficiency and safety, potentially making esophageal cancer screening more accessible and effective.

PAVmed's subsidiary, Veris Health, has launched a pilot program in collaboration with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). This program marks the first enrollment of patients on the Veris Cancer Care Platform, a comprehensive digital tool designed to enhance personalized cancer care. The platform integrates remote physiological data collection, symptom reporting, telehealth, and electronic health record capabilities. Cancer patients utilize the VerisBox and a patient portal for seamless data transmission and monitoring. Veris is also developing an implantable physiological monitor to complement the platform. The collaboration aims to improve early complication detection, reduce unplanned hospitalizations, and increase patient satisfaction.

Lucid Diagnostics announced that its EsoGuard® Esophageal DNA test has been used on the 4,000th firefighter as part of the #CheckYourFoodTube Precancer Testing Event, held by Mass General Brigham physicians and Boston Firefighters Local 718. The event aims to address the elevated risk of esophageal cancer among firefighters. This milestone event is part of Lucid Diagnostics' broader strategy to increase test volumes and highlights the importance of early cancer detection. Firefighters face a 62% higher risk of developing esophageal cancer and a 39% higher risk of dying from it. Estimates from the American Cancer Society suggest 22,370 new cases and 16,130 deaths from esophageal cancer in 2024.

PAVmed (NASDAQ: PAVM) provided a business update and reported financial results for Q1 2024. The company held a webcast on May 14, 2024, to discuss the results. Lucid Diagnostics, a subsidiary, completed a $29.8 million Series B offering, securing key reimbursement milestones. Veris Health signed an MOU with The Ohio State's James Cancer Hospital. Financially, PAVmed reported $1.0 million in EsoGuard revenues, flat quarter-over-quarter but a 124% increase from Q1 2023. Operating expenses were $15.0 million with a GAAP net loss of $22.8 million. Cash reserves stood at $25.5 million as of March 31, 2024.

Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, provided a business update and financial results for the first quarter of 2024. The company reported a 10% increase in EsoGuard test volume, a strengthened balance sheet after a $29.8 million Series B Preferred Stock Offering, and a MolDX pre-submission meeting scheduled for July 17, 2024. Lucid also highlighted revenue growth, clinical study outcomes, and market access strategy.